FDA's Cure For The Flu: Orphan Drug-Like Incentives, Tissue-Based Production
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency plans to request congressional action on influenza vaccine incentives during three hearings on the flu vaccine shortage. FDA, in cooperation with U.K. regulatory officials, will determine in January whether Chiron will be able to manufacture Fluvirin at the company’s Liverpool facility for the 2005-06 flu season.
You may also be interested in...
Cell-Culture Manufacturing Key To Boosting Flu Vaccine Supply, FDA Says
Congress’ top priority in strengthening the flu vaccine supply should be funding research in cell-cultured manufacturing, FDA Acting Commissioner Crawford tells Senate committee. However, even with cell-culture technology, flu vaccine market is unlikely to regain all of its previous suppliers, he suggests.
Cell-Culture Manufacturing Key To Boosting Flu Vaccine Supply, FDA Says
Congress’ top priority in strengthening the flu vaccine supply should be funding research in cell-cultured manufacturing, FDA Acting Commissioner Crawford tells Senate committee. However, even with cell-culture technology, flu vaccine market is unlikely to regain all of its previous suppliers, he suggests.
FDA's Crawford Readies Himself For "Intense Week" Of Congressional Hearings
FDA Acting Commissioner Lester Crawford will appear in front of four congressional committees this week in what amounts to "the most intense week of congressional hearings that we have had in FDA's history," he said